WO2009054458A1 - 血中の糖、マロンジアルデヒド修飾ldl、ホモシステイン及び／又はｃ反応性タンパク質を低減するための組成物 - Google Patents

血中の糖、マロンジアルデヒド修飾ldl、ホモシステイン及び／又はｃ反応性タンパク質を低減するための組成物 Download PDF

Info

Publication number
WO2009054458A1
WO2009054458A1 PCT/JP2008/069244 JP2008069244W WO2009054458A1 WO 2009054458 A1 WO2009054458 A1 WO 2009054458A1 JP 2008069244 W JP2008069244 W JP 2008069244W WO 2009054458 A1 WO2009054458 A1 WO 2009054458A1
Authority
WO
WIPO (PCT)
Prior art keywords
malondialdehyde
homocysteine
glucose
blood
reducing
Prior art date
Application number
PCT/JP2008/069244
Other languages
English (en)
French (fr)
Inventor
Susumu Kawaguchi
Original Assignee
Nutri Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nutri Co., Ltd. filed Critical Nutri Co., Ltd.
Priority to ES08841027.9T priority Critical patent/ES2664826T3/es
Priority to CA2703645A priority patent/CA2703645C/en
Priority to US12/739,701 priority patent/US10383893B2/en
Priority to CN200880112375A priority patent/CN101835477A/zh
Priority to DK08841027.9T priority patent/DK2221059T3/en
Priority to KR1020107011255A priority patent/KR101290514B1/ko
Priority to JP2009538253A priority patent/JP5798717B2/ja
Priority to EP08841027.9A priority patent/EP2221059B1/en
Publication of WO2009054458A1 publication Critical patent/WO2009054458A1/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

　血中の糖、マロンジアルデヒド修飾LDL、ホモシステイン及び／又はＣ反応性タンパク質を低減するための組成物を提供する。 　下記の(a)及び(b)の成分を含む、血中の糖、マロンジアルデヒド修飾LDL、ホモシステイン及びＣ反応性タンパク質からなる群より選択される少なくとも１つを低減するための組成物。 (a)ビタミンＢ１2、ビタミンＢ６及び葉酸からなる群から選ばれる少なくとも一つの成分 (b) 亜鉛、セレン及び抗酸化ビタミンからなる群から選ばれる少なくとも一つの成分
PCT/JP2008/069244 2007-10-25 2008-10-23 血中の糖、マロンジアルデヒド修飾ldl、ホモシステイン及び／又はｃ反応性タンパク質を低減するための組成物 WO2009054458A1 (ja)

Priority Applications (8)

Application Number Priority Date Filing Date Title
ES08841027.9T ES2664826T3 (es) 2007-10-25 2008-10-23 Composición para reducir el nivel glucosa, LDL modificada con malondialdehído, homocisteína y/o proteína c-reactiva en sangre
CA2703645A CA2703645C (en) 2007-10-25 2008-10-23 Composition for reducing the level of glucose, malondialdehyde-modified ldl, homocysteine and/or c-reactive protein in blood
US12/739,701 US10383893B2 (en) 2007-10-25 2008-10-23 Composition for reducing the level of glucose, malondialdehyde-modified LDL, homocysteine and/or C-reactive protein in blood
CN200880112375A CN101835477A (zh) 2007-10-25 2008-10-23 用于降低血中的糖、丙二醛修饰ldl、同型半胱氨酸和/或c反应蛋白的组合物
DK08841027.9T DK2221059T3 (en) 2007-10-25 2008-10-23 Composition for reducing the level of glucose, malondialdehyde-modified LDL, homocysteine and / or c-reactive protein in blood
KR1020107011255A KR101290514B1 (ko) 2007-10-25 2008-10-23 혈중의 당, 말론디알데히드 수식 ｌｄｌ, 호모시스테인 및/또는 ｃ 반응성 단백질을 저감시키기 위한 조성물
JP2009538253A JP5798717B2 (ja) 2007-10-25 2008-10-23 血中の糖、マロンジアルデヒド修飾ｌｄｌ、ホモシステイン及び／又はｃ反応性タンパク質を低減するための組成物
EP08841027.9A EP2221059B1 (en) 2007-10-25 2008-10-23 Composition for reducing the level of glucose, malondialdehyde-modified ldl, homocysteine and/or c-reactive protein in blood

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-277140 2007-10-25
JP2007277140 2007-10-25

Publications (1)

Publication Number Publication Date
WO2009054458A1 true WO2009054458A1 (ja) 2009-04-30

Family

ID=40579560

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/069244 WO2009054458A1 (ja) 2007-10-25 2008-10-23 血中の糖、マロンジアルデヒド修飾ldl、ホモシステイン及び／又はｃ反応性タンパク質を低減するための組成物

Country Status (9)

Country Link
US (1) US10383893B2 (ja)
EP (1) EP2221059B1 (ja)
JP (1) JP5798717B2 (ja)
KR (1) KR101290514B1 (ja)
CN (2) CN101835477A (ja)
CA (1) CA2703645C (ja)
DK (1) DK2221059T3 (ja)
ES (1) ES2664826T3 (ja)
WO (1) WO2009054458A1 (ja)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011236191A (ja) * 2010-05-11 2011-11-24 Shunzo Kobayashi 動脈硬化改善剤
WO2012141018A1 (ja) * 2011-04-15 2012-10-18 ライオン株式会社 組成物、及び糖代謝改善剤、並びに糖代謝改善方法
JP2014501759A (ja) * 2010-12-21 2014-01-23 ネステク ソシエテ アノニム 動物の血糖管理に適した方法及び組成物

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018220224A1 (en) 2017-06-02 2018-12-06 Medirista Biotechnologies Ab Lipid-related antigens and antibodies directed against them
CN111239292B (zh) * 2019-10-24 2022-11-25 丁芬 同时检测多种脂溶性维生素和同型半胱氨酸的方法
CN115702906A (zh) * 2021-08-09 2023-02-17 深圳奥萨制药有限公司 一种预防改善心血管疾病的组合物

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06192105A (ja) * 1992-09-14 1994-07-12 Vesta Medicines Pty Ltd ホモシステインのレベルを下げるための医薬製剤
JP2002504928A (ja) * 1997-06-19 2002-02-12 ライコード・ナチユラル・プロダクツ・インダストリーズ・リミテツド Ｌｄｌの酸化を防止するための天然組成物
JP2002348244A (ja) * 2001-05-23 2002-12-04 Fancl Corp 抗糖尿病組成物
JP2003504333A (ja) * 1999-07-14 2003-02-04 ラクスディル リミテッド 必須脂肪酸およびホモシステイン低下剤を含有する製剤および栄養組成物
JP2003509389A (ja) * 1999-09-14 2003-03-11 ナチュラル コンパウンズ リミテッド 天然抽出された及び合成血糖低減性又は血中脂質低減性組成物
JP2003530410A (ja) * 2000-04-14 2003-10-14 マーズ インコーポレイテッド 血管の健康状態を改善するための組成物および方法
JP2004217669A (ja) * 1992-06-05 2004-08-05 Viatris Gmbh & Co Kg 抗糖尿病用医薬およびその製造方法
JP2005524655A (ja) * 2002-02-26 2005-08-18 メルック・エプロバ・アクチエンゲゼルシヤフト 炎症及び炎症に関連する疾患の予防及び治療に適する、特に炎症マーカーｃｒｐ及びｓａａに影響を与えるのに適する調合物の製造にホラートを使用する方法
JP2006513717A (ja) * 2003-03-31 2006-04-27 カウンシル・オブ・サイエンティフィック・アンド・インダストリアル・リサーチ 血糖降下食品、およびその配合物の製造方法
JP2006306820A (ja) * 2005-05-02 2006-11-09 Nippon Menaade Keshohin Kk 低密度リポタンパク質（ｌｄｌ）酸化抑制剤

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4927850A (en) 1988-04-08 1990-05-22 Bayless Robert K Antioxidant compositions and methods for ameliorating inflammatory symptoms of respiratory disease
JPH06504259A (ja) * 1990-05-16 1994-05-19 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 高コレステロール血症および細胞過増殖性障害の予防および処置用処方および方法
US5569670A (en) 1992-06-05 1996-10-29 Asta Medica Aktiengesellschaft Combination medications containing alpha-lipoic acid and related
IL121112A (en) 1997-06-19 2005-11-20 Lycored Natural Prod Ind Ltd Synergistic pharmaceutical or dietary compositionscomprising lycopene and vitamin e for preventing ldl oxidation
US6274170B1 (en) * 1999-02-18 2001-08-14 Richard Heibel Compounds for cardiovascular treatment comprising multi-vitamin and anti-platelet aggregating agents and methods for making and using the same
US6361800B1 (en) 2000-04-13 2002-03-26 Cooper Concepts, Inc. Multi-vitamin and mineral supplement
US7208180B2 (en) * 2000-05-08 2007-04-24 N.V. Nutricia Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith
US20040037892A1 (en) 2001-11-19 2004-02-26 Adrianne Bendich Dietary composition containing conjugated linoleic acid and calcium for improved health
WO2002047493A2 (en) * 2000-12-16 2002-06-20 Aventis Pharma Deutschland Gmbh Health promoting compositions
IT1320180B1 (it) 2000-12-29 2003-11-26 Hunza Di Marazzita Maria Carme Preparazioni nutrizionali e terapeutiche dotate di attivita'antiossidante ed in grado di controllare gli eccessi ponderali e
US20060116334A1 (en) 2004-12-01 2006-06-01 Curt Hendrix Folate based composition for treatment of the cardiovascular system
CN1320925C (zh) * 2005-03-30 2007-06-13 淮北市辉克药业有限公司 长期使用的治疗糖尿病的复方制剂
CA2620366C (en) * 2005-08-26 2014-04-01 Nestec S.A. Nutrition for obese patients
JP2007106703A (ja) * 2005-10-14 2007-04-26 Nutri Kk 血管障害の予防および治療組成物
ATE509624T1 (de) * 2005-12-23 2011-06-15 Nutricia Nv Zusammensetzung enthaltend mehrfach ungesättigte fettsäuren, proteine, mangan und/oder molybden und nukleotide/nukleoside, zur behandlung von demenz
DE202006014588U1 (de) * 2006-09-20 2006-12-14 Orthomol Pharmazeutische Vertriebs Gmbh Carotinoide-enthaltendes Produkt
US20080102137A1 (en) * 2006-10-31 2008-05-01 Guffey Manning V R Composition and method for etiological treatment and prevention of diseases and/or complications associated with chronic glucose metabolism destabilization
US20080318883A1 (en) * 2007-06-19 2008-12-25 Elson Corporation Anti-aging supplement

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004217669A (ja) * 1992-06-05 2004-08-05 Viatris Gmbh & Co Kg 抗糖尿病用医薬およびその製造方法
JPH06192105A (ja) * 1992-09-14 1994-07-12 Vesta Medicines Pty Ltd ホモシステインのレベルを下げるための医薬製剤
JP2002504928A (ja) * 1997-06-19 2002-02-12 ライコード・ナチユラル・プロダクツ・インダストリーズ・リミテツド Ｌｄｌの酸化を防止するための天然組成物
JP2003504333A (ja) * 1999-07-14 2003-02-04 ラクスディル リミテッド 必須脂肪酸およびホモシステイン低下剤を含有する製剤および栄養組成物
JP2003509389A (ja) * 1999-09-14 2003-03-11 ナチュラル コンパウンズ リミテッド 天然抽出された及び合成血糖低減性又は血中脂質低減性組成物
JP2003530410A (ja) * 2000-04-14 2003-10-14 マーズ インコーポレイテッド 血管の健康状態を改善するための組成物および方法
JP2002348244A (ja) * 2001-05-23 2002-12-04 Fancl Corp 抗糖尿病組成物
JP2005524655A (ja) * 2002-02-26 2005-08-18 メルック・エプロバ・アクチエンゲゼルシヤフト 炎症及び炎症に関連する疾患の予防及び治療に適する、特に炎症マーカーｃｒｐ及びｓａａに影響を与えるのに適する調合物の製造にホラートを使用する方法
JP2006513717A (ja) * 2003-03-31 2006-04-27 カウンシル・オブ・サイエンティフィック・アンド・インダストリアル・リサーチ 血糖降下食品、およびその配合物の製造方法
JP2006306820A (ja) * 2005-05-02 2006-11-09 Nippon Menaade Keshohin Kk 低密度リポタンパク質（ｌｄｌ）酸化抑制剤

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
"Plasma homocysteine levels and mortality in patients with coronary artery disease", N ENGL J MED, vol. 337, no. 4, 1997, pages 230 - 6
JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, vol. 202, no. 10, 2002, pages 789 - 793
JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, vol. 218, no. 1, 1 July 2006 (2006-07-01)
KEIKO ET AL., THE JAPANESE JOURNAL OF CLINICAL NUTRITION, vol. 108, no. 2, February 2006 (2006-02-01)
SANEKATA, KAZUHIRO: "Development and clinical evaluation of MDA-LDL measurement system", THE 13TH MEETING OF THE SOCIETY OF ANALYTICAL BIO-SCIENCE
See also references of EP2221059A4
TAKAHASHI, HAKUO: "High sensitive C-reactive protein: hs-CRP", THROMBOSIS AND CIRCULATION, vol. 12, no. 4, 2004
YAMANAKA, TAKAO ET AL., JAPANESE SOCIETY OF PSYCHOSOMATIC MEDICINE, vol. 46, no. 4, April 2006 (2006-04-01)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011236191A (ja) * 2010-05-11 2011-11-24 Shunzo Kobayashi 動脈硬化改善剤
JP2014501759A (ja) * 2010-12-21 2014-01-23 ネステク ソシエテ アノニム 動物の血糖管理に適した方法及び組成物
WO2012141018A1 (ja) * 2011-04-15 2012-10-18 ライオン株式会社 組成物、及び糖代謝改善剤、並びに糖代謝改善方法

Also Published As

Publication number Publication date
CA2703645A1 (en) 2009-04-30
CN104224835A (zh) 2014-12-24
JP5798717B2 (ja) 2015-10-21
US20100247505A1 (en) 2010-09-30
EP2221059A4 (en) 2010-12-15
KR101290514B1 (ko) 2013-07-26
EP2221059A1 (en) 2010-08-25
US10383893B2 (en) 2019-08-20
CA2703645C (en) 2015-01-27
DK2221059T3 (en) 2018-03-12
CN101835477A (zh) 2010-09-15
EP2221059B1 (en) 2018-01-17
ES2664826T3 (es) 2018-04-23
KR20100080560A (ko) 2010-07-08
JPWO2009054458A1 (ja) 2011-03-10

Similar Documents

Publication Publication Date Title
WO2009054458A1 (ja) 血中の糖、マロンジアルデヒド修飾ldl、ホモシステイン及び／又はｃ反応性タンパク質を低減するための組成物
WO2007149724A3 (en) Substrates for performing analytical reactions
WO2009006389A8 (en) Pyrimidine derivatives useful as raf kinase inhibitors
WO2007121252A3 (en) Tandem photovoltaic cells
WO2008073420A3 (en) Systems and methods for treating patient hypertonicity
WO2007120962A3 (en) Adjusting ph in a method of separating whole blood
BRPI0506726A (pt) especìfico para m-csf e seus deste
WO2008005375A3 (en) Kidney toxicity biomarkers
WO2007092755A3 (en) Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
WO2010056981A3 (en) Methods and compositions for regulating iron homeostasis by modulation bmp-6
WO2007124361A3 (en) Soluble b7-h1
BRPI0822955A2 (pt) método para operar um elevdor em um modo de emergência, e, elevador.
WO2007117487A3 (en) Methods and systems for disturbance rejection in dc-to-dc converters
WO2009085969A3 (en) Compositions and methods to promote implantation and engrafment of stem cells
WO2007038624A3 (en) Stable acidic beverage emulsions and methods of preparation
WO2009073905A8 (de) Verfahren zur erhöhung der immunreaktivität
WO2009124294A3 (en) Pharmaceutical compositions for binding sphingosine-1-phosphate
BRPI0719272A2 (pt) Composição de enzima, e, método para preparar uma composição de enzima.
WO2006118884A3 (en) Drug delivery devices and related components, systems and methods
WO2008046865A3 (en) Long-term feed - elderly
WO2008070169A3 (en) Use of carboxyamidotriazole (cai) orotate in macular degeneration
WO2010057647A3 (en) Methods and compositions for the diagnosis and treatment of diabetes
WO2008059041A3 (en) Complementation of factor xi deficiency by factor v mutants
WO2013101771A3 (en) Compositions and method for treating autoimmune diseases
WO2008061248A3 (en) Phenylsulfoxyoxazole compound inhibitors of urea transporters

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880112375.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08841027

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009538253

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 12739701

Country of ref document: US

Ref document number: 2703645

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008841027

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20107011255

Country of ref document: KR

Kind code of ref document: A